355 related articles for article (PubMed ID: 29990500)
21. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
Maurus K; Hufnagel A; Geiger F; Graf S; Berking C; Heinemann A; Paschen A; Kneitz S; Stigloher C; Geissinger E; Otto C; Bosserhoff A; Schartl M; Meierjohann S
Oncogene; 2017 Sep; 36(36):5110-5121. PubMed ID: 28481878
[TBL] [Abstract][Full Text] [Related]
22. The PGF(2alpha) receptor FP is lost in nevi and melanoma.
Fricke A; McClelland L; Scott G
Pigment Cell Melanoma Res; 2010 Feb; 23(1):141-3. PubMed ID: 20002888
[No Abstract] [Full Text] [Related]
23. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.
Hoek K; Rimm DL; Williams KR; Zhao H; Ariyan S; Lin A; Kluger HM; Berger AJ; Cheng E; Trombetta ES; Wu T; Niinobe M; Yoshikawa K; Hannigan GE; Halaban R
Cancer Res; 2004 Aug; 64(15):5270-82. PubMed ID: 15289333
[TBL] [Abstract][Full Text] [Related]
24. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
25. Integrative analysis of the melanoma transcriptome.
Berger MF; Levin JZ; Vijayendran K; Sivachenko A; Adiconis X; Maguire J; Johnson LA; Robinson J; Verhaak RG; Sougnez C; Onofrio RC; Ziaugra L; Cibulskis K; Laine E; Barretina J; Winckler W; Fisher DE; Getz G; Meyerson M; Jaffe DB; Gabriel SB; Lander ES; Dummer R; Gnirke A; Nusbaum C; Garraway LA
Genome Res; 2010 Apr; 20(4):413-27. PubMed ID: 20179022
[TBL] [Abstract][Full Text] [Related]
26. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
27. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.
Dar AA; Majid S; Rittsteuer C; de Semir D; Bezrookove V; Tong S; Nosrati M; Sagebiel R; Miller JR; Kashani-Sabet M
J Natl Cancer Inst; 2013 Mar; 105(6):433-42. PubMed ID: 23365201
[TBL] [Abstract][Full Text] [Related]
28. Trajectories of premalignancy during the journey from melanocyte to melanoma.
Colebatch AJ; Scolyer RA
Pathology; 2018 Jan; 50(1):16-23. PubMed ID: 29132722
[TBL] [Abstract][Full Text] [Related]
29. Identification of key candidate genes involved in melanoma metastasis.
Chen J; Wu F; Shi Y; Yang D; Xu M; Lai Y; Liu Y
Mol Med Rep; 2019 Aug; 20(2):903-914. PubMed ID: 31173190
[TBL] [Abstract][Full Text] [Related]
30. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.
Verfaillie A; Imrichova H; Atak ZK; Dewaele M; Rambow F; Hulselmans G; Christiaens V; Svetlichnyy D; Luciani F; Van den Mooter L; Claerhout S; Fiers M; Journe F; Ghanem GE; Herrmann C; Halder G; Marine JC; Aerts S
Nat Commun; 2015 Apr; 6():6683. PubMed ID: 25865119
[TBL] [Abstract][Full Text] [Related]
31. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.
Mordoh A; Triviño Pardo JC; Carri I; Barrio MM; Mordoh J; Aris M
BMC Med Genomics; 2023 Jan; 16(1):1. PubMed ID: 36604730
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.
Ticha I; Hojny J; Michalkova R; Kodet O; Krkavcova E; Hajkova N; Nemejcova K; Bartu M; Jaksa R; Dura M; Kanwal M; Martinikova AS; Macurek L; Zemankova P; Kleibl Z; Dundr P
Sci Rep; 2019 Nov; 9(1):17050. PubMed ID: 31745173
[TBL] [Abstract][Full Text] [Related]
33. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
34. Somatic Hypermutation of the
Zhang X; Tang JZ; Vergara IA; Zhang Y; Szeto P; Yang L; Mintoff C; Colebatch A; McIntosh L; Mitchell KA; Shaw E; Rizos H; Long GV; Hayward N; McArthur GA; Papenfuss AT; Harvey KF; Shackleton M
Mol Cancer Res; 2019 Jul; 17(7):1435-1449. PubMed ID: 30833299
[TBL] [Abstract][Full Text] [Related]
35. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
Forloni M; Dogra SK; Dong Y; Conte D; Ou J; Zhu LJ; Deng A; Mahalingam M; Green MR; Wajapeyee N
Elife; 2014 Feb; 3():e01460. PubMed ID: 24550252
[TBL] [Abstract][Full Text] [Related]
36. A majority of human melanoma cell lines exhibits an S phase-specific defect in excision of UV-induced DNA photoproducts.
Bélanger F; Rajotte V; Drobetsky EA
PLoS One; 2014; 9(1):e85294. PubMed ID: 24416382
[TBL] [Abstract][Full Text] [Related]
37. microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB.
Giles KM; Brown RA; Ganda C; Podgorny MJ; Candy PA; Wintle LC; Richardson KL; Kalinowski FC; Stuart LM; Epis MR; Haass NK; Herlyn M; Leedman PJ
Oncotarget; 2016 May; 7(22):31663-80. PubMed ID: 27203220
[TBL] [Abstract][Full Text] [Related]
38. Melanoma progression.
Elder DE
Pathology; 2016 Feb; 48(2):147-54. PubMed ID: 27020387
[TBL] [Abstract][Full Text] [Related]
39. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases.
Koh SS; Wei JP; Li X; Huang RR; Doan NB; Scolyer RA; Cochran AJ; Binder SW
Mod Pathol; 2012 Jun; 25(6):828-37. PubMed ID: 22411186
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathogenesis of cutaneous melanocytic neoplasms.
Ibrahim N; Haluska FG
Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
